News & Analysis on the Clinical Development and Manufacture of Large Molecule Drugs
Cue Biopharma has released positive data at SITC 2022 from its ongoing Phase 1 trial evaluating its lead interleukin 2 (IL-2)-based biologic, CUE-101, in combination with KEYTRUDA, as a first line therapy for patients with recurrent/metastatic HPV+ head...
A therapy from Alexion, AstraZeneca’s Rare Disease group, is now available in China.
Phase 3 studies evaluating gantenerumab failed to meet the primary endpoint of slowing clinical decline.
BioNTech will create an mRNA facility in Singapore through the acquisition of a Novartis site: which will become its Regional Headquarters and production center for the Asia Pacific region.